Hoth Therapeutics (HOTH) Reports Positive HT-VA CRADA Data: GDNF Reprograms Liver Fat Metabolism, Shuts Down Fat-Creation Gene and Activates Fat-Burning Pathways, Outperforming Semaglutide

Semaglutide has been the go-to peptide for metabolic research, but new data from Hoth Therapeutics is shaking things up. In a recent release, Hoth Therapeutics announced results from their HT-VA CRADA study showing their research compound GDNF did more than just tweak liver metabolism—it rewired it. The standout: GDNF not only suppressed the gene that creates new fat in the liver but also kicked fat-burning pathways into high gear. In direct comparisons, GDNF outperformed semaglutide on these key metabolic switches.

What does this mean for peptide researchers? The bar just got higher. Semaglutide has been widely studied for its ability to regulate appetite and glucose, but Hoth’s data points to a new target—direct reprogramming of liver fat metabolism.

Key highlights from the release:

This changes the conversation around metabolic research peptides. Researchers now have another tool to compare against the established benchmarks. Anyone sourcing peptides like semaglutide for metabolic or obesity research will want to keep an eye on these new data sets. The fact that GDNF can outpace semaglutide in some pathways suggests the metabolic peptide field is far from settled.

With more competition and new research compounds in the pipeline, the pace of data in the metabolic peptide space is only going to speed up. Researchers looking for sourcing options or the latest updates should check the vendor directory for the newest entries.

Bottom line: Semaglutide isn’t the only heavyweight in liver fat metabolism anymore. Keep watching this space.